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lyzed wheat protein allergy due to
a facial soap in JapanTo the Editor:
Wheat proteins in hydrolyzed form have been widely used in
cosmetic products. The number of patients allergic to hydrolyzed
wheat protein (HWP) in cosmetic products seems to be small in
Western countries (see Table E1 and this article’s Online
Repository at www.jacionline.org). However, in Japan, Fukutomi
et al1 first reported 5 Japanese patients with wheat-dependent
exercise-induced anaphylaxis (WDEIA) after using the
facial soap containing 0.3% of a specific type of HWP,
Glupearl 19S, in 2009, and thousands of subjects showed allergic
contact urticaria, anaphylaxis, and/orWDEIA after using the soap.
Here, we provide an overview of the outbreak of immediate-
type wheat allergy caused by a specific HWP (HWP-IWA) by
facial soaps in Japan.
A nationwide survey for HWP-IWA was conducted to collect
the information on Glupearl 19S–containing soaps. A flowchart
of the patient registration and the diagnostic criteria are shown in
Fig E1 and Table E2, respectively, and details are also described in
this article’s Online Repository at www.jacionline.org.
On the basis of the diagnostic criteria listed in Table E2, the
number of patients who satisfied the diagnostic criteria was
2111 (2025 females, 86 males; age, 1-93 years; average age,
45.86 14.5 years). The age group with the largest share consisted
of those in their 40s (see Fig E2 in this article’s Online Repository
at www.jacionline.org). Because sales of the soap containing Glu-
pearl 19S were discontinued inMay 2011, the number of reported
patients has gradually decreased, and the nationwide survey for
HWP-IWA ended in October 2014 (Fig 1).
The symptoms typically appeared 1 year after starting use of the
soap. Most patients used the soap only for their faces, but some
used it on other body parts as well. Symptoms observed in patients
are listed in Table I. No patients had shown apparent wheat allergy
before using this soap. Twenty-five percent of patients experi-
enced anaphylactic shock, 43% experienced dyspnea, and 11%
experienced vomiting. Most of the patients with food ingestion–
related symptoms reacted to traditional wheat products such as
bread and pasta. This was in contrast to non-Japanese patients
allergic to HWP in cosmetic products, who tolerated traditional
wheat products but showed the symptoms of allergic reaction after
eating processed food such as ham and pa^te (see Table E1 and On-
line Repository). Initial symptoms of anaphylaxis in the patients 2017 The Authors. Published by Elsevier Inc. on behalf of the American Academy of
Allergy, Asthma & Immunology. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).were facial symptoms, including swelling of the eyelids, urti-
caria/itchiness of the face, and runny nose, which were distinct
from conventional WDEIAwith initial symptoms of systemic re-
action of itching and urticaria.
In contrast to conventional wheat allergies that react mainly
with gliadin and high molecular weight glutenin in wheat
protein,2 immunoblot analysis and ELISA revealed that sera
from patients allergic to the HWP-containing soap showed a
pattern distinct from that of conventional wheat allergy.1
Glupearl 19S that was produced by acid treatment of gluten
(pH, 0.5-1.2) at 958C for 40 minutes is the HWP responsible for
the allergenicity of the soap. The SDS-PAGE analysis of Glupearl
19S showed a smear staining pattern from the low to high molec-
ular weight range in contrast to the staining pattern of gluten. Fig
E3 in this article’s Online Repository at www.jacionline.org
shows the SDS-PAGE of Glupearl 19S and IgE reactivity against
Glupearl 19S by ELISA3 (see this article’s Methods section in the
Online Repository at www.jacionline.org) using sera obtained
from conventional patients with WDEIA, patients with HWP-
IWA who satisfied the diagnostic criteria, subjects who had
used soaps containing Glupearl 19S but did not meet the diag-
nostic criteria, and healthy controls. As shown in Fig E3, strong
IgE reactions were observed only in those patients who satisfied
the diagnostic criteria, and none of the sera obtained from patients
with conventional WDEIA reacted with Glupearl 19S.
Because patients used the soap repeatedly on the face, it is
likely that allergen exposure occurred through the eyelids and
noses, leading to the strong allergic reactions with their eyelids
that were not commonly observed in patients with conventional
wheat allergy. Airaksinen et al4 reported 2 patients of occupa-
tional rhinitis, asthma, and contact urticaria due to a sprayable
hair conditioner containing HWP, and both of them showed
exercise-induced eyelid edema and other symptoms after eating
wheat-containing food.
Glupearl 19S was produced by acid treatment of gluten (pH,
0.5-1.2) at 958C for 40 minutes. It has been reported that
gluten treated with 0.1 N hydrochloric acid for 30 minutes at
1008C markedly increased IgE-binding capacity of patients’
sera, indicating that neoepitopes on the gluten might be
generated after the treatment.5 The acid treatments at high
temperature for a short time produce random degradation of
gluten, and mixed short and long peptides, leading to smear
pattern by electrophoresis (Fig E3). Because most food prod-
ucts do not contain HWP, it was speculated that gastrointes-
tinal enzyme reaction after ingestion of wheat protein might
be responsible for acquiring allergenicity. Glupearl 19S itself
is not deamidated by transglutaminase in the body, but deami-
dated peptides were produced during the process of acid and
heat treatment of gluten,6 and then specific IgE antibodies
against Glupearl 19S were produced when patients used the
soap repeatedly (Fig E3). Nakamura et al7 showed that tissue
transglutaminase treatment of gluten dramatically increased
reactivity against IgE from the patients’ sera by cell-based
assay (EXiLE). Yokooji et al8 reported that IgE-binding
epitope QPQQPFPQ in g-gliadin reacted more strongly with
IgE of the patients in its deamidated form, PEEPFP.8 Ingested
wheat food product such as bread and/or pasta might be deami-
dated by transglutaminase in the body, and specific IgE anti-
bodies against Glupearl 19S could cross-react with
deamidated peptide derived from food gluten, which may
lead to anaphylactic/allergic reaction in the patients.
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FIG 1. The number of patients registered per month and cumulative total number between 2012 and 2014.
TABLE I. Symptoms observed in immediate-type wheat allergy
caused by Glupearl 19S (n 5 899)
Skin symptoms during or after using soap, n (%)
Skin symptoms 640 (71)
Swelling of eyelids 360 (40)
Urticaria, itching, and rubefaction 280 (31)
Skin symptoms negative 246 (27)
Unknown 13 (2)
Symptoms after eating wheat products, n (%)
Swelling of eyelids 694 (77)
Urticaria 537 (60)
Dyspnea 385 (43)
Erythema 344 (38)
Itching 278 (31)
Anaphylactic shock 227 (25)
Diarrhea 148 (16)
Nausea 122 (14)
Nasal discharge 117 (13)
Vomiting 103 (11)
Nasal congestion 95 (11)
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880 LETTERS TO THE EDITORThe detailed analysis of allergenicity of HWP and predispo-
sition to type I allergy against HWP will lead to the safe use of
cosmetic products containing wheat protein.
Hiragun et al9 reported the status of remission of 110 patients
with IWA-HWP who were part of the 2111 patients mentioned
above, and the remission rate of 110 patients was still 56.1% at
60 months after stopping usage of HWP-containing soap. There-
fore, it is necessary to find effective treatment for the long-lasting
and refractory cases. Discovering the molecular mechanisms un-
derlying the HWP-IWA, in comparison with conventional
WDEIA and wheat intolerance such as celiac diseases, may
lead to better understanding of the molecular basis of wheat pro-
tein–related diseases.
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signaling networks in primary
immunodeficiency diseasesTo the Editor:
We describe here an approach to improve diagnoses and further
our understanding of functional defects of primary immunodefi-
ciency diseases (PIDs) using time-of-flight mass cytometry
(CyTOF) to reveal the signaling of all circulating immune cells.
PIDs were historically diagnosed by a narrow, pathognomonic
constellation of signs and symptoms. However, ever-broadening
phenotypes have become apparent for diseases such as gain-of-
function signal transducer and activator of transcription (STAT) 1.
Moreover, distinct geneticmutationsmay share a single phenotype,
especially if they share a signaling pathway (eg, LPS responsive
beige-like anchor [LRBA] deficiency and cytotoxic T lymphocyte–associated antigen 4 haploinsufficiency). Thus, there has been an
increasing reliance on genetic definitions of PIDs. However,
sequencing cannot identify whether a novel mutation in a ‘‘known
PID gene’’ will lead to a loss-of-function phenotype, a gain-of-
function phenotype, or no phenotype at all. In this ‘‘postexome’’ era,
identification of immune diseases would be greatly facilitated by a
broad, unbiased functional analysis that parallels the broad, unbi-
ased genetic analysis provided by next-generation sequencing.
This proof-of-concept study shows the potential of CyTOF to
characterize a broad range of cells and signals. We began by
testing the responses of circulating immune cells to canonical
stimuli (cytokines and TLR agonists) in 5 healthy controls.
Samples of whole blood were aliquoted and portions were
stimulated with a cytokine or TLR agonists (IFN-a, IL-2, IL-5,
IL-6, IL-7, IL-10, IL-17, IL-21, IL-25, LPS, and PMA) for
15 minutes; 1 aliquot was left unperturbed. We used CyTOF to
measure more than 40 different markers simultaneously,
including 9 intracellular phospho-proteins involved in signaling
pathways (p38, ERK, PLCg2, STAT1, STAT3, STAT5, S6 kinase,
IkB, and AKT). We identified 18 types of circulating innate and
adaptive immune cell types in the blood by gating (see Fig E1 in
this article’s Online Repository at www.jacionline.org) and exam-
ined phospho-signaling responses in these cell types at baseline
and after stimulation (Fig 1; see Tables E1 and E2 in this article’s
Online Repository at www.jacionline.org). Examining responses
after 15-minute stimulations minimized the impact of secondary
signals that might arise at later time points.
This approach identified known patterns of stimuli and
responses spanning both lymphoid and myeloid lineages
including granulocytes, such as STAT5 in response to IL-2 and
IL-7 and STAT3 in response to IL-6 and IL-10 (Fig 1). We noted
that activated CD41 and CD81 T cells, respectively, had minimal
or no increase in pSTAT5 in response to IL-7. In contrast, resting
memory or naive T-cell lineages showed strong responses. These
results can be explained by the reduced expression of IL-7 recep-
tor in activated T cells.1 Notably, IL-7R was not used in gating.
Thus, our algorithm detected patterns of differential responses
to IL-7 without an a priori understanding of IL-7R expression.
Hierarchical clustering indeed showed that functional signaling
responses largely mirrored developmental lineages (see Fig E2
in this article’s Online Repository at www.jacionline.org). Inter-
estingly, we found that myeloid dendritic cells, plasmacytoid den-
dritic cells, and CD161monocytes clustered with lymphoid cells,
while CD162 monocytes clustered with myeloid cells. This
grouping may reflect the functional propensity of CD161 mono-
cytes to differentiate into dendritic cells.2 These results show
that even cells within the same developmental lineages may
have varying degrees of responses to stimuli.
To demonstrate the utility of CyTOF in elucidating PIDs with
broad phenotypes, we studied 2 patients with PID as a proof-of-
principle. We started with an adolescent patient with chronic
mucocutaneous candidiasis (CMC) identified with a monoallelic
mutation in STAT1 (p.R274W), producing a GOF phenotype.
CMC in these patients has been attributed to defective TH17 im-
munity.3We first examinedwhether any baseline phosphorylation
in our GOF STAT1 subject fell outside the 95% CI established in
controls. At baseline, we unexpectedly found increased STAT3
phosphorylation in T cells (Fig 2, A). We did not find increased
STAT1 phosphorylation at baseline, consistent with many previ-
ous studies. Next, we examined responses of the GOF STAT1 sub-
ject to stimuli as compared with controls (see Fig E3 in this
METHODS
MEDLINE searches for patients allergic to HWP in
cosmetic products outside of Japan
We used PubMed (http://www.ncbi.nlm.nih.gov/pubmed/) to search the
National Library of Medicine andMEDLINE to collect information about pa-
tients allergic to HWP. For the electronic searches, we used a combination of
keywords related to ‘‘hydrolyzed wheat protein’’ and ‘‘allergy/anaphylaxis,’’
thenmanually excluded patients allergic to HWP in food.We included articles
published in English or thosewith English translations available.We also used
the information published in Scientific Committee on Consumer Safety in
2014.E1
Nationwide survey for HWP-IWA
The soap, Yuuka-no-sekken, commonly known as Cha-no-shizuku soap
(Yuuka, Fukuoka, Japan) containing Glupearl 19S (Katayama Chemical
Industries, Osaka, Japan), was sold only by mail order between March
2004 and December 2010. Glupearl 19S was derived from wheat gluten,
and had not been exported to other domestic/foreign companies. The soap
was very popular, especially among women, due to the advertised effects
of beautifying and whitening the skin. The number of registered customers
at Yuuka, the company selling the soap, was 4,667,000, and the total
number of soaps sold to the customers was 46,508,000.E2 On the basis of
the number of adult Japanese women, 54,444,000,E3 it was estimated that
approximately 1 in 12 Japanese adult women used the soap. The Special
Committee for the Safety of Protein Hydrolysates in Cosmetics was
formed by the Japanese Society of Allergology, and the diagnostic criteria
were established in October 2011, with patient registration beginning in
April 2012. Among hospitals/clinics eligible for proper diagnosis, 270
clinics/hospitals reported confirmed cases of HWP-IWA by the facial
soaps to the Special Committee. Fig E1 shows the flowchart of patient
registration. Subjects who experienced any symptoms after using the soap
and/or ingestion of wheat products contacted the company that sold the
soaps (Yuuka), the Ministry of Health, Labour, and Welfare of Japan,
the Consumer Affairs Agency of Japan, or the Japanese Society of Aller-
gology. They provided information regarding which clinics/hospitals pro-
vided proper diagnosis for HWP-IWA and which could perform skin prick
tests using Glupearl 19S and/or specific IgE antibody detection tests for
Glupearl 19S. The Glupearl 19S specific IgE antibody detection test was
provided in the laboratory organized by the Special Committee. Some con-
sumers visited clinics/hospitals directly, and some of them were referred to
allergy/dermatology specialists for proper diagnosis. Because the informa-
tion regarding allergic symptoms and usage of the soaps was provided
from many resources, including the company (Yuuka), the Consumer Af-
fairs Agency of Japan, the Japanese Society of Allergology, and the Min-
istry of Health, Labour, and Welfare of Japan, and the incident was also
covered in the mass media, it is considered that we covered most of the
cases of the incident.
IgE measurements in patients with allergy to
Glupearl 19S and other wheat-related allergies
SDS-PAGE. SDS-PAGE was performed using Novex NuPAGE 4% to
12% gels and MOPS buffer (Thermo Fisher Scientific, Waltham, Mass)
according to the manufacturer’s instructions. Separated proteins of Glupearl
19S and gluten were stained with SimplyBlue SafeStain (Thermo Fisher
Scientific).
ELISA for Glupearl 19S. Subjects. Sera were obtained from patients
with conventional WDEIAwho reacted to v-5 gliadin (n 5 7), patients with
HWP-IWAwho satisfied the diagnostic criteria described in Table E2 (n5 20),
subjects who had used soaps containing Glupearl 19S but who did not satisfy
the diagnostic criteria (ie, skin prick test negative using 0.1%Glupearl 19S so-
lution, n5 20), and healthy controls without wheat allergy (n5 7). The study
was approved by the Ethics Committee of Fujita Health University (11-210),
and informed consent was obtained from each patient. This study was carried
out in accordance with the Declaration of Helsinki.
ELISA. Details of the ELISAmethod were described previously.E4 Briefly,
1 mg/mL Glupearl 19S was plated on a Nunc MaxiSorp flat-bottom 96-well
plate (Thermo Fisher Scientific). The plate was blocked with 1% skim milk/
PBS containing 0.1% Tween 20. After washing, diluted patients’ sera was
added to each well, and the plate was incubated. The plate was washed,
0.1 mg/mL antihuman IgE antibody horseradish peroxidase conjugate (KPL,
Gaithersburg, Md) was added to each well, and the plate was incubated.
The plate was washed, and the colorimetric reaction was developed by adding
1-Step Ultra TMB-ELISA (Thermo Fisher Scientific). Absorbance values at
450 nm were measured by VersaMax (Molecular Devices, Sunnyvale, Calif),
and were converted into units, as described previously, and cutoff values were
set at 5.0 units.
RESULTS AND DISCUSSION
MEDLINE searches for patients allergic to HWP in
cosmetic products outside of Japan
A list of non-Japanese patients allergic to HWP in cosmetic
products is given in Table E1.E4-E15 Many of the patients used
facial creams, and some used sprayable hair conditioner contain-
ing HWP.E15 As shown in Table E1, some had no symptoms
related to ingestion of food, whereas others showed allergic symp-
toms after eating foods containing wheat. Interestingly, most of
the patients tolerated traditional wheat products, such as bread
and pasta, but allergic reactions occurred after eating processed
food containing HWP, such as ham and liver pa^te.E9,E12,E13
Among hospitals/clinics eligible for proper diagnosis, 270
clinics/hospitals reported confirmed cases of HWP-IWA by the
facial soaps to the Special Committee. After a careful examina-
tion at the clinics/hospitals, 2111 subjects were confirmed to be
satisfied with the diagnostic criteria. Doctors who treated the
confirmed cases were asked to participate in an online survey, and
clinical details of 899 patients were reported to the Special
Committee (Table I).
Causality between Glupearl 19S and HWP-IWA was consid-
ered as follows. (1) Patients showed symptoms related to type I
allergy after using soap containing Glupearl 19S, and showed
symptoms repeatedly. (2) Skin prick test, ELISA, or basophil
activation test against Glupearl 19S was positive. This reactivity
was not observed in patients with traditional WDEIA and in
healthy controls (Fig E3). (3) These symptoms, including allergic
reactions after ingestion of wheat products, had not been observed
before starting use of soap containing Glupearl 19S.
Among 2111 confirmed cases, the past/present history of
allergic diseases was available in 899 patients. Allergic rhinitis/
pollinosis, atopic dermatitis, urticaria, and asthma were observed
in 297 (33%), 107 (12%), 42 (5%), and 17 (2%), respectively.
There was no increase in the prevalence of allergic rhinitis/
pollinosis and asthma in HWP-allergic patients compared with
the prevalence in a general population survey of allergic rhinitis/
pollinosis (47.2%) and adult asthma (5.4%), but the incidence of
atopic dermatitis, the prevalence of which in the general popu-
lation was reported to be 9.4% for those in their 20s, 8.3% in the
30s, and 4.8% in the 40s, slightly increased.E16
Fig E3 shows an SDS-PAGE image of Glupearl 19S and
gluten. Glupearl 19S was produced by acid treatment of gluten
(pH, 0.5-1.2) at 958C for 40 minutes. The acid treatments at
high temperature for a short time produce random degradation
of gluten, and mixed short and long peptides, leading to smear
pattern by electrophoresis. Other researchers also showed a
similar smear pattern of electrophoresis using Glupearl 19S.E17
Acid treatment of gluten at high temperature for a long period
J ALLERGY CLIN IMMUNOL
VOLUME 140, NUMBER 3
LETTERS TO THE EDITOR 881.e1
(24 hours) produced only small peptides that are not allergenic,E18
but Glupearl 19S contains short and long peptides that could
cause allergic reaction in the patients. Glupearl 19S itself is not
deamidated by transglutaminase in the body, but deamidated pep-
tides were produced during the process of acid and heat treatment
of gluten,E18 and then specific IgE antibodies against Glupearl
19S were produced while patients used the soap repeatedly
(Fig E3). Ingested wheat food product such as bread and/or pasta
might be deamidated by transglutaminase in the body, and spe-
cific IgE antibodies against Glupearl 19S could cross-react with
deaminated peptide derived from food gluten, which may lead
to anaphylactic/allergic reaction in the patients.
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Subjects who experienced allergy related symptoms aer using the soap 
and/or ingeson of wheat products
Total number of the soap consumers (n = 4,667,000)
Clinics/hospitals 
with no specialists
Clinics/hospitals with 
allergy/dermatology specialists
eligible for proper diagnosis
• 270 clinics/hospitals reported conﬁrmed cases to the Special Commiee
• The conﬁrmed cases who sasﬁed the diagnosc criteria (n = 2,111) 
• The conﬁrmed cases with clinical details available (n = 899).
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FIG E1. Flowchart of the patients’ registration for immediate-type wheat allergy caused by a specific HWP
(HWP-IWA).
J ALLERGY CLIN IMMUNOL
VOLUME 140, NUMBER 3
LETTERS TO THE EDITOR 881.e3
0100
200
300
400
500
600
700
800
0-9 years 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80-89 90 and over
N
um
be
r o
f p
at
ie
nt
s
Male Female
FIG E2. Age and sex distribution of the Japanese patients allergic to HWP in facial soaps.
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FIG E3. IgE antibody levels against Glupearl 19S. A, SDS-PAGE image of Glupearl 19S and gluten. M: mo-
lecular weight marker; lane 1: Glupearl 19S, lane 2: gluten. B, Dot plots of serum Glupearl 19S specific IgE
levels were quantified by ELISA using sera from patients with conventional WDEIA (CO-WDEIA, n 5 7),
HWP-IWA who satisfied the diagnostic criteria described in Table E2 (HWP, n 5 20), subjects who had
used the soaps but who did not satisfy diagnostic criteria (HWP-Negative, n 5 20), and healthy controls
without wheat allergy (Healthy, n 5 7). Units greater than 100 are described as 100. Dashed line indicates
a cutoff value (5 units).
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TABLE E1. Non-Japanese patients allergic to HWP in cosmetic products
Year Authors
No. of
patients Country Cosmetic products
Symptoms after
applying cosmetics
Symptoms after eating
wheat-containing food Reference
2000 Sanchez-Perez et al 1 Spain Moisturizing cosmetic
cream
Contact urticaria NA E5
2000 Varjonen et al 1 Finland Body cream Contact dermatitis/urticaria NA E4
2002 Pecquet et al 1 France Eyelid cream, body
moisturizer
Generalized urticaria Generalized urticaria E6
2004 Pecquet et al 7 France Facial creams Contact dermatitis Anaphylaxis/urticaria
(6 patients)
E7
2006 Codreanu et al 3 France Shower gel, shampoo,
mascara
Generalized erythema,
contact eczema, facial
angioedema with
generalized urticaria
WDEIA (1 patient) E8
2006 Lauriere et al 9 France Facial creams, body
moisturizer, shower gel,
hair conditioner
Contact urticaria Generalized urticaria
(3 patients), anaphylaxis
(2 patients), WDEIA
(1 patient)
E9
2007 Hann et al 1 United Kingdom Moisturizing cosmetic
cream
Contact dermatitis NA E10
2007 Livideanu et al 1 France Emollient Contact dermatitis NA E11
2010 Bouchez-Mahiout et al 4 France Skin tensing cosmetic,
facial cream
Contact urticaria Urticaria (1 patient),
exercise-induced
food allergy (1 patient)
E12
2010 Olaiwan et al 2 France Cosmetics Contact urticaria Generalized urticaria
(1 patient)
E13
2012 Barrientos et al 1 Spain Skin cream Contact dermatitis No symptoms related to
ingestion of the food
E14
2013 Airaksinen et al 2 Finland Sprayable hair
conditioner
Occupational rhinitis,
asthma, contact
urticaria
WDEIA (1 patient),
exercise-induced food
allergy (1 patient)
E15
NA, Not available.
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TABLE E2. Diagnostic criteria for immediate wheat allergy to HWP (Glupearl 19S)
Individual must meet all the following criteriaE4-E6
Criteria 1 (usage of soaps):
1. History of usage of Cha-no-Shizuku soap or other products containing hydrolyzed wheat (Glupearl 19S)
Criteria 2 (symptoms), either of the following:
1. Itching, eyelid edema, nasal discharge, and/or wheals within several to 30 min after using Cha-no-Shizuku soap or other products containing hydrolyzed
wheat (Glupearl 19S)
2. General symptoms, such as itching, wheals, eyelid edema, nasal discharge, dyspnea, nausea, vomiting, abdominal pain, diarrhea, and decreased blood
pressure, within 4 h after eating wheat products
Criteria 3 (laboratory test positive), either of the following:
1. Skin prick test using <_0.1% Glupearl 19S solution
2. Immunoassay, such as dot blot, ELISA, and/or western blot to identify specific IgE antibody to Glupearl 19S in the serum/plasma
3. Basophil activation test using Glupearl 19S
Exclusion criterion
Skin prick test negative using 0.1% Glupearl 19S solution
Defined by the Special Committee for the Safety of Protein Hydrolysates in Cosmetics on October 11, 2011.
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